Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis

被引:44
作者
Shapiro, DE
Sperling, RS
Mandelbrot, L
Britto, P
Cunningham, BE
机构
[1] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA
[2] Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY USA
[3] Hop Cochin Port Royal, Serv Gynecol Obstet 1, Paris, France
[4] Frontier Sci & Technol Res Fdn Inc, Amherst, MA USA
关键词
D O I
10.1016/S0029-7844(99)00451-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To identify modifiable obstetric factors associated with the failure of zidovudine chemoprophylaxis to prevent perinatal human immunodeficiency virus type 1 (HIV-1) transmission. Methods: We analyzed data from Pediatric AIDS Clinical Trials Group protocol 076, a randomized, double-masked, placebo-controlled trial that demonstrated that a zidovudine regimen could prevent perinatal HIV-1 transmission. We estimated the zidovudine treatment effect using the relative reduction in transmission risk among women randomized to treatment with zidovudine compared with women randomized to receive placebo. Univariate and multivariate statistical analyses were used to assess whether the treatment effect differed in magnitude according to potential antepartum or intrapartum risk factors. Results: In the univariate analysis, the zidovudine treatment effect was found to differ significantly in magnitude according to quartile of maternal weight at the time of study entry (interaction test, P = .03); among women in the heaviest-weight quartile (weight more than 82 kg), there was a 26% relative reduction in transmission risk, compared with a 79% relative reduction among the other three quartiles (interaction test, P = .05). In the zidovudine treatment group, women who transmitted HIV-1 were significantly more likely than nontransmitters to have had antepartum procedures or conditions associated with increased risk of fetal exposure to maternal blood or cervicovaginal secretions (43% compared with 19%, P = .04). In the multivariate analysis, adjustment for the plasma HIV-1 RNA level and CD4(+) cell percentage did not eliminate the differential treatment effect according to these factors. Conclusion: High maternal weight and conditions associated with fetal exposure to maternal blood or cervicovaginal secretions may diminish the efficacy of zidovudine chemoprophylaxis. (Obstet Gynecol 1999;94:897-908. (C) 1999 by The American College of Obstetricians and Gynecologists.).
引用
收藏
页码:897 / 908
页数:12
相关论文
共 38 条
[1]   Clinical pharmacokinetics of zidovudine - An update [J].
Acosta, EP ;
Page, LM ;
Fletcher, CV .
CLINICAL PHARMACOKINETICS, 1996, 30 (04) :251-262
[2]   A United States national reference for fetal growth [J].
Alexander, GR ;
Himes, JH ;
Kaufman, RB ;
Mor, J ;
Kogan, M .
OBSTETRICS AND GYNECOLOGY, 1996, 87 (02) :163-168
[3]  
[Anonymous], 1992, MMWR Recomm Rep, V41, P1
[4]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[5]  
[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1
[6]  
[Anonymous], MMWR
[7]   FACTORS PREDICTIVE OF MATERNAL-FETAL TRANSMISSION OF HIV-1 - PRELIMINARY-ANALYSIS OF ZIDOVUDINE GIVEN DURING PREGNANCY AND/OR DELIVERY [J].
BOYER, PJ ;
DILLON, M ;
NAVAIE, M ;
DEVEIKIS, A ;
KELLER, M ;
OROURKE, S ;
BRYSON, YJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (24) :1925-1930
[8]  
Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P1005
[9]   REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].
CONNOR, EM ;
SPERLING, RS ;
GELBER, R ;
KISELEV, P ;
SCOTT, G ;
OSULLIVAN, MJ ;
VANDYKE, R ;
BEY, M ;
SHEARER, W ;
JACOBSON, RL ;
JIMENEZ, E ;
ONEILL, E ;
BAZIN, B ;
DELFRAISSY, JF ;
CULNANE, M ;
COOMBS, R ;
ELKINS, M ;
MOYE, J ;
STRATTON, P ;
BALSLEY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180
[10]   After AIDS clinical trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants [J].
Cooper, ER ;
Nugent, RP ;
Diaz, C ;
Pitt, J ;
Hanson, C ;
Kalish, LA ;
Mendez, H ;
Zorrilla, C ;
Hershow, R ;
Moye, J ;
Smeriglio, V ;
Fowler, MG ;
Rich, K ;
Turpin, D ;
PachecoAcosta, E ;
Tuomala, R ;
Mesthene, D ;
Fox, H ;
Higgins, A ;
Landesman, S ;
Moroso, G ;
Willoughby, A ;
Sheon, A ;
McKinlay, S ;
Sherrieb, K .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) :1207-1211